Related Experiment Videos
Immunologic differentiation between E. coli and CHO cell-derived recombinant and natural human beta-interferons
Journal of Immunology (Baltimore, Md. : 1950)
|December 1, 1984
Summary
Recombinant human interferon-beta (IFN-beta) produced in E. coli, CHO cells, and fibroblasts show similar hydrophobic properties but differ in glycosylation and antibody neutralization. These differences allow for specific differentiation of IFN-beta variants.
Area of Science:
- Biotechnology
- Immunology
- Protein Chemistry
Background:
- Interferon-beta (IFN-beta) is a crucial therapeutic protein.
- Understanding post-translational modifications and their impact on protein function is vital for biopharmaceutical development.
- Different expression systems yield proteins with varying characteristics.
Purpose of the Study:
- To characterize and compare human IFN-beta produced in Escherichia coli (E. coli), Chinese Hamster Ovary (CHO) cells, and human fibroblasts.
- To investigate the impact of expression systems on IFN-beta's physical, chemical, and immunological properties.
- To identify methods for differentiating between these IFN-beta variants.
Main Methods:
- Purification using monoclonal antibody columns.
- Analysis by reverse-phase High-Performance Liquid Chromatography (HPLC).
- Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) to determine molecular weight.
- Antibody neutralization assays using monoclonal and polyclonal antibodies.
- Radioimmunoassay (RIA) for antibody binding measurements.
Main Results:
- Proteins purified from all three sources showed similar hydrophobic properties via HPLC.
- SDS-PAGE revealed molecular weight differences: E. coli-derived IFN-beta (17,000 Da) vs. CHO and fibroblast IFN-beta (23,000 Da), attributed to glycosylation (26% of m.w.).
- Antibody neutralization assays demonstrated distinct specificities: CHO-IFN-beta preferentially neutralized by anti-HuIFN-beta antibodies, while E. coli-IFN-beta was preferentially neutralized by anti-E. coli-IFN-beta antibodies.
- Radioimmunoassays indicated similar binding affinities to anti-HuIFN-beta antibodies across all variants.
Conclusions:
- Human IFN-beta expressed in E. coli, CHO cells, and fibroblasts exhibit distinct characteristics, primarily due to glycosylation differences.
- These variants can be effectively differentiated using specific antibody cross-reactivity profiles.
- The findings are crucial for quality control and characterization of recombinant IFN-beta products.